DIA 2013 49th Annual Meeting
Click here to go to the previous page
TransCelerate's Collaborative Approach to Risk-based Monitoring: The Methodology
Track : Track 21: Late Breaker
Program Code: 363
Date: Wednesday, June 26, 2013
Time: 1:45 PM to 3:15 PM  EST
Location: 206AB
CHAIR :
 Craig Wozniak, (SPKNON), Head, Americas Clinical Operations, GlaxoSmithKline, United States
SPEAKER (S):
 Michael B. Luker, MBA (SPKNON), Senior Advisor, Eli Lilly and Company, United States
Craig Wozniak, (SPKNON), Head, Americas Clinical Operations, GlaxoSmithKline, United States
Description
TransCelerate BioPharma Inc. (TransCelerate) developed a methodology for monitoring that shifts monitoring processes from an excessive concentration on source data verification to comprehensive risk-driven monitoring. This philosophical shift in monitoring processes employs centralized and offsite mechanisms to identify and monitor important study parameters holistically and uses adaptive onsite monitoring to further support subject safety and data quality.